Navigation Links
CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
Date:2/26/2008

l by dialing (866) 524-6247, and international callers may participate in the conference call by dialing (706) 679-3061. Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through Tuesday, March 4, 2008. Domestic callers can access the replay by dialing (800) 642-1687, and international callers can access the replay by dialing (706) 645-9291; the PIN access number is 32378484.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

CV Therapeutics also has other clinical and preclinical drug development candidates and programs, including regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies, and CVT-6883, which is being developed as a potential treatment for cardiopulmonary diseases. Regadenoson and CVT-6883 have not been determined by any regulatory authorities to be safe or effective in humans for any use.

Except for the historical information contained herein, the matters set forth in this press release, including statements as to research and development and commercialization of products, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, includi
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
2. Hsiao Dee Lieu, M.D., F.A.C.C. Named VP of Clinical Research of Nile Therapeutics
3. The Diabetes Series 2008: Experts Speak About Developing Diabetes Therapeutics
4. CV Therapeutics Announces Presentations at the American College of Cardiology 57th Annual Scientific Session
5. Sirion Therapeutics Acquires Worldwide License to Develop New Treatment for Ocular Diseases
6. Ocera Therapeutics Closes $35.5 Million Series C Financing
7. Amsterdam Molecular Therapeutics Reports Full Year Results 2007
8. United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results
9. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
10. Cell Therapeutics, Inc. (CTI) Announces Cancellation of Approximately $9.1 Million of Existing Notes due 2008
11. PeriCor Therapeutics Appoints K. Tucker Andersen to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2008)...s at Singapore,s Institute of Bioengineering and N...of imidazolium salts (IMSs), which suggest that th...nd treatment. , The report on the redox propert...merican Chemical Society . , In a separate study...tion , IBN researchers reported the first use of t...
(Date:12/2/2008)... Ariz., Dec. 2 MedPredict Market R...etitive intelligence and market,research, has pub...nsight for,pharma and biotech companies with a st...erapies. This report, entitled Thought Leader Ins...sed on 9 interviews conducted with PD,experts fro...
(Date:12/2/2008)... Calif., Dec. 2 Bionovo,... focused on the discovery and,development of safe...h and,cancer, announced that Isaac Cohen, Chairma...iew of the Company at the 20th Annual Piper Jaffra...r 3, 2008. The event will be held at,the New Yor...
(Date:12/2/2008)...A, Dec. 2 eResearchTechn...rovider of centralized ECG and eClinical,technolo... biotechnology,medical device and related indust...y, the Company,s President and Chief Executive Off...ncial Officer, are scheduled to present at,the Pi...
Breaking Biology Technology:New uses for imidazolium salts in medicine and alternative energy 2New uses for imidazolium salts in medicine and alternative energy 3New Report Provides Expert Analysis of Recent Advances and Setbacks in Parkinson's Disease Drug Development 2Bionovo to Present at the Piper Jaffray Healthcare Conference 2eResearchTechnology, Inc. to Present at the Piper Jaffray Health Care Conference on December 2, 2008 2
...y Systems Inc. said it has raised $1.4 million in... , ,The company, now about a year old, is developi...generating and using hydrogen fuel in car engines.... method involves generating it from water and suga...ve a chemical reaction. , ,The firm said Advantage...
Culver,s, a fast-food chain native to Wisconsin, is working with Madison Environmental Group on a kit to make cars run on old frying oil. Meanwhile, online extortionists are holding personal files fo
...t tolerating unexpected difference. The boxes tend...a spike in their power curve or an unanticipated c... us that way. The difference, of course, is our ab...e recognize it and choose to do something about it...ok like their pets. Do we begin to look like, act ...
...rket failed to reach double-digit growth in 2004 f... for this focused on concerns over drug safety, pr...products had their patents expire. , ,Let,s take a...the estimates of IMS Health, a pharmaceutical mark...e pharmaceutical market slowed down, one important...
Other Biology Technology:Machine like me 2Machine like me 3Though pharma growth slides, blockbusters reach new record 2Though pharma growth slides, blockbusters reach new record 3
(Date:12/1/2008)...D, Calif. Scientists around the world may benefit...online, that will help them to home in on the part..., Arend Sidow, PhD, associate professor of pathol...ool of Medicine, recently launched the novel bioin...de to determining the role different proteins play...
(Date:12/1/2008)...National Academy of Sciences will hold a colloquiu...es of the nature of niches of organisms. Leading r...predict future patterns of distribution and even e...ology, phylogenetics, and biodiversity informatics...of the Sackler Colloquium series, the event will t...
(Date:12/1/2008)...r, CO, USA The December Geosphere , The Geologic...Topics include detailed data integration from mult...dimentology, and paleontology, to study the southw...ion years ago; sedimentation in a piggyback basin;..., Nevada; and a study of the South Balkan extensio...
(Date:12/1/2008)...IDENCE, R.I. [Brown University] Gray mold is a ga...scientific name Botrytis cinerea , is a scourge t...species, including staples such as tomatoes, straw... endive, peas, peppers, and potatoes. Gray mold en...oxin that poisons the host plants, cells, eventual...
Breaking Biology News(10 mins):Powerful online tool for protein analysis provided pro bono by Stanford geneticist 2Powerful online tool for protein analysis provided pro bono by Stanford geneticist 3December Geosphere media highlights 2December Geosphere media highlights 3Brown chemist finds gray mold's killer gene 2CyberKnife System Achieves 38 Percent Growth in Extracranial Treatments During Fiscal Year 2008 8564 1CyberKnife System Achieves 38 Percent Growth in Extracranial Treatments During Fiscal Year 2008 8564 2CyberKnife System Achieves 38 Percent Growth in Extracranial Treatments During Fiscal Year 2008 8564 3CyberKnife System Achieves 38 Percent Growth in Extracranial Treatments During Fiscal Year 2008 8564 4Angiotech Announces Webcast and Call in Numbers for Annual and Special General Meeting of Shareholders 8561 1Johnson 26 Johnson Pharmaceutical Research 26 Development L L C Submits New Drug Application to FDA for Carisbamate 8559 1Johnson 26 Johnson Pharmaceutical Research 26 Development L L C Submits New Drug Application to FDA for Carisbamate 8559 2Johnson 26 Johnson Pharmaceutical Research 26 Development L L C Submits New Drug Application to FDA for Carisbamate 8559 3Technique for Rapidly Reprogramming Adult Cells Into Stem Cells Published in PLoS Biology 3332 1Technique for Rapidly Reprogramming Adult Cells Into Stem Cells Published in PLoS Biology 3332 2Technique for Rapidly Reprogramming Adult Cells Into Stem Cells Published in PLoS Biology 3332 3
..., a director at the Max Planck Institute of Bioche...the beginning of the 1990s that blocking blood ves... and shrinks its tissue. This fundamental principl...ingredient is Sunitinib. SUTENT® was recently appr... is expected to be brought onto the German market ...
...Comprehensive Cancer Center say that just one, sin...e cancer in mice. The discovery offers new insight...d lymphoma and at the same time underscores the po... RNA play in cell signaling pathways active in car...s is the first direct evidence that overexpression...
...ysed rocks from seabeds millions of years old. Car...ass 12 (99 percent) and atomic mass 13 (1 percent)...were characterised by a relatively strong increase...sed by a sudden large-scale release of carbon from...s. , The atmospheric carbon dioxide concentration...
...ept at blending in with their surroundings, cuttle...terns and can switch between them almost instantan...entists, to appear in the May 2006 issue of the jo...asters of disguise change their appearance based o...olorblind. , While previous research has reported ...
Other Biology News:Basic research leads to a novel cancer therapy 2Basic research leads to a novel cancer therapy 3Basic research leads to a novel cancer therapy 4Single microRNA causes cancer in transgenic mouse 2Single microRNA causes cancer in transgenic mouse 3Carbon cycle was already disrupted millions of years ago 2Cuttlefish masters of disguise despite colorblindness 2
ANTI ALPHA FSH:B
Beagle Serum • Beagle serum is collected from fasted Beagle canines of mixed sex over one year of age Available Anticoagulants: N-02: Citrate N-04: Heparin (Na) N-06: K2EDTA N-08: Pot
MOUSE ANTI HUMAN MBP (67-74) Immunogen: Human myelin basic protein
MOUSE ANTI BOVINE TROPONIN I
Biology Products: